Drugs / ONO-2952
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01613703 | Aug 2012 → Mar 2013 | — | Ono Pharma USA Inc | Completed | No outcome recorded |
| Phase 1 | NCT01489345 | Dec 2011 → Apr 2012 | — | Ono Pharma USA Inc | Completed | No outcome recorded |
| Phase 1 | NCT01364441 | May → Aug 2011 | — | Ono Pharma USA Inc | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT01887002 | Jun 2013 → Jan 2015 | irritable bowel syndrome | Ono Pharma USA Inc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01844180 | Apr 2013 → Jul 2014 | irritable bowel syndrome | Ono Pharma USA Inc | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-2952 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01364441 ↗ |
| Action | Inhibit | “novel translocator protein 18 kDa antagonist ONO-2952” PMID 26249232 ↗ Aug 20151“Translocator protein antagonist” CHEMBL4297311 ↗ |
| Modality | Small molecule | — CHEMBL4297311 ↗ |
| Target | TSPO | “Translocator protein antagonist” CHEMBL4297311 ↗ |